Compass Therapeutics (CMPX) Change in Account Payables (2019 - 2026)

Compass Therapeutics has reported Change in Account Payables for 8 years, with the latest figure at -$679000.0 in Q1 2026.

• Quarterly Change in Account Payables fell 1.04% year-over-year to -$679000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$671000.0 (down 192.81% YoY) and the FY2025 annual result came in at -$664000.0, up 63.93% from the prior year.
• Change in Account Payables improved to -$679000.0 in Q1 2026 per CMPX's latest filing, from -$1.5 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $6.2 million in Q2 2022 and troughed at -$3.7 million in Q3 2022.
• A 5-year average of $2294.1 and a median of -$232000.0 in 2024 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 62200.0% in 2022, down 1295.47% in 2022.
• Over 5 years, Change in Account Payables stood at $621000.0 in 2022, then soared by 187.28% to $1.8 million in 2023, then declined by 27.75% to $1.3 million in 2024, then plunged by 217.15% to -$1.5 million in 2025, then jumped by 55.03% to -$679000.0 in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$679000.0, -$1.5 million, and $500000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.